

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International BureauExp Mail EV449562444US  
USAN 10/648,854

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>C07K</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 92/08731</b> <b>(43) International Publication Date:</b> 29 May 1992 (29.05.92)
<b>(21) International Application Number:</b> PCT/US91/08022 <b>(22) International Filing Date:</b> 30 October 1991 (30.10.91) <b>(30) Priority data:</b> 607,293 30 October 1990 (30.10.90) US <b>(71) Applicant:</b> LA JOLLA CANCER RESEARCH FOUNDATION [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US). <b>(72) Inventor:</b> RANSCHT, Barbara ; 560 Rimini Road, Del Mar, CA 92014 (US). <b>(74) Agents:</b> CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).		<b>(81) Designated States:</b> AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU <sup>+</sup> , TD (OAPI patent), TG (OAPI patent).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> T-CADHERIN ADHESION MOLECULE  <b>(57) Abstract</b>  The invention provides substantially purified T-cadherin polypeptides and isolated nucleic acids which encode the T-cadherin polypeptides. Antibodies reactive with various forms of T-cadherin, but not reactive with N-, E- or P-cadherin are also provided. The invention provides methods for detecting the various forms of T-cadherin in a subject as well as a method of inhibiting tumor cell migration which consists of increasing tumor cell adhesion with an effective amount of T-cadherin. A method of repairing traumatized neurons is provided. The method entails treating traumatized neurons with a therapeutically effective dose of T-cadherin.		

# **+ DESIGNATIONS OF "SU"**

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## **FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

## T-CADHERIN ADHESION MOLECULE

## BACKGROUND OF THE INVENTION

This invention relates to cell surface molecules and more specifically to T-cadherin, a new cell adhesion molecule of the cadherin family.

Cadherins are a family of transmembrane glycoproteins that mediate adhesive interactions in the developing and adult organism through a  $\text{Ca}^{2+}$ -dependent mechanism (Takeichi, 1988 and 1990, review). It has been suggested that the cadherins arose from a common ancestral gene. Duplication of the gene may have resulted in the formation of a structurally related family of molecules with heterogeneous sequences. Cadherins share their overall structure which, at the extracellular region, is subdivided into a signal peptide, a prepeptide and five related extracellular domains and is followed by a transmembrane domain and a highly conserved stretch of cytoplasmic amino acids, that is suggested to provide a linkage with the cell's cytoskeletal network. The signal peptide and the prepeptide are readily cleaved and are absent from the mature protein. Several members of the cadherin family have been characterized. N-cadherin is found in the nervous system during development and has been shown to be a strong mediator of nerve fiber growth in vitro. In addition to neural tissue, N-cadherin is also expressed in heart and skeletal muscle and in lens cells. E-cadherin (also known as uvomorulin in the mouse) is a component of epithelial cells and P-cadherin is found in placenta.

T-cadherin, which is subject of this application, is a novel member to the cadherin family that shares the overall cadherin structure in the extracellular region, but lacks the conserved cytoplasmic sequences. Therefore, a new mode of T-cadherin function is proposed, in which T-

cadherin regulates the adhesive cell properties not through a direct linkage with the cytoskeleton, but through higher membrane mobility and ready access to its extracellular ligand. The pattern of T-cadherin expression suggests a key role in the establishment of the pattern of nerve fiber growth in developing embryos. Furthermore, T-cadherin is the first molecularly characterized polypeptide to be identified in a segmental pattern as epithelial somites undergo the transition to form the dermamyotome and sclerotome. The expression in only one half of the somitic sclerotome, that eventually will give rise to vertebrae, suggests that T-cadherin plays a key role in the segmentation of vertebrate embryos. Segmentation is a crucial property of the vertebral column that allows flexibility and provides an individual with the ability to bend the back. T-cadherin has also been identified in muscle cells and blood vessels. In muscle, T-cadherin may be involved in cell differentiation and function. T-cadherin has also been found in blood vessels.

The identification of molecules which regulate and direct nerve fiber growth is important to the study of nerve regeneration. After being severed, neurons either degenerate or remain in a state of severe atrophy. The prognosis for recovery of these damaged neurons is very poor. Therefore, the use of molecules such as the T-cadherin cell adhesion molecules may influence neurons to regrow their axons and guide the axons to reinnervate their corresponding target cells. Eventually, this may lead to relief from the disabling effects of stroke or trauma to the nervous system.

There thus exists a need for the identification and characterization of cell surface adhesion molecules which may be involved in regulation of development in the embryo or recovery of traumatized neurons including methods of detecting and utilizing these molecules. The present

invention satisfies this need and provides related advantages as well.

#### SUMMARY OF THE INVENTION

The invention provides substantially purified T-cadherin polypeptides and isolated nucleic acids which encode the T-cadherin polypeptides. Antibodies reactive with various forms of T-cadherin, but not reactive with N-, E- or P-cadherin are also provided. The invention provides methods for detecting the various forms of T-cadherin in a subject as well as a method of inhibiting tumor cell migration which consists of increasing cell adhesion with an effective amount of T-cadherin. A method of repairing traumatized neurons is further provided. The method entails treating traumatized neurons with a therapeutically effective dose of T-cadherin.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the STRUCTURAL alignment of T-cadherin 1 (266 cDNA) and T-cadherin 2 (1212 cDNA) with the cadherin consensus structure.

Figure 2 shows the nucleotide and predicted amino acid sequence of the T-cadherins. Figure 2a is the sequences of T-cadherin 1. Figure 2b shows the sequences for T-cadherin 2.

Figure 3 shows the amino acid alignment of T-cadherin 1 (266 cDNA) with the related proteins N-cadherin, L-CAM, E-cadherin and P-cadherin.

Figure 4 is an immunoblot of various tissues isolated from 3 day old chicks using antiserum to T-cadherin. Polypeptides having an  $M_r$  of 90, 110 and 120 kD are detected in neural tissues whereas only the 90 and 110 kD

polypeptides are detected in non-neural tissues. Lane 1, spinal cord; lane 2, midbrain; lane 3, cerebellum; lane 4, cortex; lane 5, optic tectum; lane 6, retina; lane 7, muscle; lane 8, heart; lane 9, kidney; lane 10, liver; lane 11, lung.

Figure 5a shows the release of T-cadherin from cultured neurons following phosphatidylinositol phospholipase C (PI-PLC) treatment by Western Blotting with T-cadherin antiserum. T-cadherin is released into the supernatant after PI-PLC treatment (lane 6). The release is blocked by treatment with  $\text{ZnCl}_2$  (lane 9). Figure 5b is an immunoprecipitation of  $^3\text{H}$ -ethanolamine labeled T-cadherin following release from cultured neurons with PI-PLC. Two polypeptides of  $M_r$  90 and 120 kD are released by PI-PLC and are precipitated with T-cadherin antiserum (lane 2).

Figure 6 is an RNA blot of brain tissue probed with a T-cadherin cDNA portion corresponding to the T-cadherin 1 EcoRI-PstI restriction fragment (1.76 kb). The probe detects two mRNA species of 7.5 and 9.5 kb.

Figure 7 shows a RNase protection assay of T-cadherin mRNA. Samples are BR = brain, M = muscle, LI = liver, H = heart, K = kidney, LU = lung, RT = retina from hatched chickens. N = cultured sympathetic neurons as in Example 5. Spinal cord H/H stage 37 and 24. Spinal cord H/H stage 24 separated into D = dorsal, V = ventral and FP = floor plate region. SOM = somites.

Figure 8 is an immunohistochemistry analysis of T-cadherin expression in the developing nervous system. The tissues examined are: (a) somites H/H stage 23; (b) developing spinal cord, panel 1, H/H stage 20, panel 2, H/H stage 24 and panel 3, H/H stage 32; (c) blood vessel; and (d) muscle.

Figure 9 shows that T-cadherin mediates homophilic cell adhesion. Equal numbers of unlabeled T-cadherin transfected and CSFE labeled control cells were mixed and allowed to aggregate. Figure 9a is the phase contrast photomicrograph of the resulting aggregates. Figure 9b is the fluorescence photomicrograph of the same field. Aggregates were formed that contained only T-cadherin transfected cells, therefore the binding is homophilic. Bar=50  $\mu$ m.

Figure 10 shows the percent aggregation of T-cadherin transfected cells. Aggregation assays were performed as described in Example XIV. Cells were treated with PI-PLC, 1  $\mu$ g/ml cytochalasin D or 1  $\mu$ g/ml nocodazole as described. The numbers represent the percent aggregation determined as described. The results are averages  $\pm$  standard deviation. Each assay was performed n number of times, each in triplicate. (\*)n = 12, (+)n = 2, and ( $\diamond$ ) n = 3.

Figure 11 shows the surface distribution of T-cadherin in aggregated cells. Figure 11a is the phase contrast photomicrograph of the transfected cells. Figure 11b shows the fluorescence photomicrograph of the same aggregate in the same field.

#### DETAILED DESCRIPTION OF THE INVENTION

T-cadherin ("T-cad;" T=truncated) is a member of the cadherin family of cell adhesion molecules. T-cadherin may be involved in the development of the embryo or recovery of traumatized neurons and therefore may be useful in nerve regeneration. T-cadherin is expressed in the nervous system, as well as the heart, skeletal muscle, blood vessels and the muscle lining the gut and skin. The high expression of T-cadherin in blood vessels may be important in the development of highly vascularized tumors.

T-cadherin shares some but not all structural features of other cadherins. The structural similarity extends to the amino acid level in that the extracellular portion of T-cadherin shows 35-47% identity with the extracellular domains of N-cadherin, E-cadherin, P-cadherin and L-CAM; N-cadherin with 47% amino acid identity being most closely related. Two forms of T-cadherin identified in the present invention lack the cytoplasmic portion found in all other members of the cadherin family. One form of T-cadherin, herein referred to as T-cad 1, appears to be anchored to the membrane through a glycosyl phosphatidylinositol (GPI) linkage. Biochemical evidence for such a linkage has been obtained by showing that T-cadherin can be released from the cellular plasma membrane by phosphatidylinositol specific phospholipase C and can incorporate radiolabeled ethanolamine into the GPI linkage. The other form of T-cadherin, T-cad 2, is predicted by the cDNA to contain sequences for a hydrophobic domain followed by 5 cytoplasmic amino acids. From preliminary transfection of this cDNA into COS-cells, it is likely that this form is also GPI-linked. These data provide evidence for a membrane linkage of T-cadherins that differs from known cadherins, in particular, in their proposed association with the cytoskeleton. In summary, T-cadherin is a member of the cadherin family of cell adhesion molecules that differs in its anchorage to the plasma membrane from known cadherins.

cDNAs have been isolated that encode T-cad 1 and T-cad 2, two closely related, but distinct forms of T-cadherin (Figures 2a and 2b). The extracellular portion of both forms are identical and contain structural features characteristic of the cadherin family. The two forms differ in their COOH-terminal region in that T-cad 2 cDNA encodes five additional amino acids (Figure 3). The absence of a cytoplasmic domain can allow for greater



mobility of these molecules within the cell membrane and therefore modulate adhesive cell properties.

RNA transcripts encoding both forms of T-cadherin have been detected using RNase protection probes specific for each form. There is evidence that the different forms of T-cadherin may be developmentally regulated both temporally and in a tissue specific fashion.

As used herein, "T-cadherin" or "T-cad" refers to polypeptides having substantially the amino acid sequence in Figures 2a and 2b, and which are cross-reactive with antibodies reactive with T-cad, but not with N-cadherin, E-cadherin, P-cadherin and L-CAM. Polypeptides comprising the extracellular, transmembrane and truncated cytoplasmic domain of T-cad 1 and T-cad 2 are provided. Minor modifications of the sequence which do not destroy its immunoreactivity also fall within the definition of the protein claimed.

The suggested open reading frame of T-cadherin cDNAs, T-cad 1 and T-cad 2, encode 690 and 695 amino acid proteins, respectively, of predicted molecular mass 76,018 and 76,627 daltons.

It is understood that limited modifications may be made without destroying the biological function of T-cadherin, and that only a portion of the entire primary structure may be required to effect activity. Minor modifications of the primary amino acid sequence may result in proteins which have substantially equivalent or enhanced function.

As used herein, "T-cadherin" refers to a cell adhesion polypeptide having an amino acid sequence substantially equivalent to that shown in Figures 2a and 2b and may be

involved in the development of the embryonal nervous system and in recovery of traumatized neurons. As used herein, "T-cadherin" also refers to active fragments of the cell adhesion polypeptide having the desired activity of the polypeptide.

"Substantially purified," when used to describe the state of T-cadherin, denotes the protein substantially free of the other proteins and molecules normally associated with or occurring with T-cadherin in its native environment.

"Nucleic acid encoding" as used herein, refers to the primary nucleotide sequence of a gene which provides the order of corresponding amino acids in the protein that they specify. Examples of the cadherin nucleic acid sequence are presented in Figures 2a and 2b.

The invention provides nucleic acids (DNA, RNA, or cDNA) encoding the polypeptides of the invention. The nucleic acid may or may not be expressed in the native host. Vectors comprising these nucleic acids are also provided. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. "Transformed host cells" refers to cells which have had vectors, constructed using recombinant DNA techniques, introduced to them. Host cells can be transformed with such a vector and used to express recombinant polypeptides. Host cells can be mammalian, yeast, insect, or bacterial as long as the appropriate vector is used. Methods of recombinant expression are well known in the art, see Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL (1982), which is incorporated herein by reference. Thus, recombinant polypeptides and the method of their production are also provided.

The vectors and methods disclosed herein are suitable for use in host cells including a wide range of prokaryotic and eukaryotic organisms. It is understood that "cells" or "host cells" refers not only to the particular subject  
5 cell, but also to the progeny of such a cell. The invention provides vectors which are capable of expressing DNA sequences contained therein, where such sequences are operably linked to other sequences capable of effecting their expression. It is implied that these expression  
10 vectors must be replicable in the host organism either as episomes or as an integral part of the chromosomal DNA.

Additionally, recombinant DNA methods currently used by those skilled in the art include the polymerase chain reaction (PCR), which, combined with the synthesis of  
15 oligonucleotides, allows easy reproduction of DNA sequences. A DNA segment can be amplified exponentially starting from as little as a single gene copy by means of PCR. In this procedure, a denatured DNA sample is incubated with two oligonucleotide primers that direct the  
20 DNA polymerase-dependent synthesis of new complementary strands. Multiple cycles of synthesis each results in an approximate doubling of the amount of target sequence. After twenty-five amplification cycles, the amount of target sequence increases by approximately  $10^6$ -fold.  
25 Amplification of first strand cDNAs using the polymerase chain reaction has been used to detect both forms of T-cadherin. The PCR technology is the subject matter of United States Patent Nos. 4,683,195; 4,800,159; 4,754,065 and 4,683,202, all of which are incorporated by reference  
30 herein. The cDNAs shown in Figures 2a and 2b, or any portion of the sequence can be reproduced for cloning and expression purposes by amplifying the desired sequence with PCR and cloning it into a suitable vector, as is well known in the art.

Detection methods for the presence of nucleic acid or protein in cells include hybridization of a nucleic acid probe with the nucleic acid of a cell and cell staining with polyclonal or monoclonal antibodies. Such techniques  
5 are accomplished by methods well-known to those skilled in the art.

Polyclonal antibodies against T-cadherin were prepared according to procedures well known in the art. The specificity of the antibodies was examined by carrying out  
10 immunohistochemistry and immunoblotting of various tissues including neuronal cells and somites.

Alternatively, anti-T-cadherin antibodies can be prepared by immunizing an animal with synthetic peptides or recombinant protein fragments prepared from the sequence  
15 shown in Figures 2a and 2b as is well known in the art. Selection of anti-T-cadherin antibodies is performed as described above.

Monoclonal antibodies are prepared by immunizing an animal with material containing T-cadherin or synthetic  
20 peptides or recombinant protein fragments thereof, followed by isolating antibody-producing hybridoma cells, as is well known in the art. (See, for example, Harlow and Lane, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor, 1988, and the references cited therein, all which are  
25 incorporated herein by reference.) Anti-T-cadherin antibodies are selected by performing immunofluorescence analysis of tissue sections where T-cadherin is localized. The identification of antibodies is confirmed by immunoblotting and immunoprecipitation which reveals the  
30 predominant 90 kD polypeptide described above. The appropriate hybridoma is reactive with purified T-cadherin or T-cadherin fragments. T-cadherin fragments can be prepared by expressing the T-cadherin cDNAs shown in

Figures 2a and 2b in a prokaryotic or eukaryotic expression vector as described above.

Methods of detecting T-cadherin in a subject are also provided. T-cadherin can be detected in a cell sample by  
5 using immunological techniques such as labeled antibodies. Such methods including the choice of label are known to those ordinarily skilled in the art. (Harlow and Lane, Supra). Briefly a subject's tissue sample is exposed first to an antibody specific for T-cadherin. After binding of  
10 the antibody, a second antibody, appropriately labeled and specific for the anti-T-cadherin antibody, is exposed to the sample previously incubated with the T-cadherin antibody. The secondary antibody can then be visualized or quantitated and the presence of T-cadherin detected.

15 The results of aggregation studies with CHO-cells transfected with the T-cadherin gene indicate that T-cadherin is associated with cell adhesion. The results are shown in Figures 9, 10 and 11. The high concentration of T-cadherin in the areas of cell-cell contact indicates that  
20 the molecules induce cells to adhere to one another in a closely packed aggregate.

It is known that tumor cells tend to lose their adhesiveness, which results in cell migration and eventual metastasis. By increasing the concentration of T-cadherin  
25 in such cells, either directly or by gene therapy, the cells can be induced to reinstate normal adhesion in order to prevent tumor cell migration.

The invention also provides a method of repairing traumatized neurons of a subject, including trauma due to  
30 stroke or injury. Administration of T-cadherin in the region of the traumatized neurons may influence neurons to regrow their axons and guide the axons to reinnervate their target cells.

The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be employed.

5

## EXAMPLE I

Isolation of T-Cadherin

T-cadherin was identified as a concanavalin A-binding glycoprotein in the detergent-resistant membrane skeleton of chicken sympathetic neurons and embryo brain. The membrane skeleton was isolated as a non-ionic detergent resistant polypeptide complex was isolated in buffer A (10 mM Tris/HCl, pH 7.6, 2 mM  $\text{CaCl}_2$ , 5% Nonident P40, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 50  $\mu\text{M}$  leupeptin, 5  $\mu\text{M}$  pepstatin, 4 ng/ml aprotinin) from 13-16 day old chick embryo brains. The 90 kD fragment of T-cadherin was separated from the complex by preparative SDS gel electrophoresis (Laemmli, Nature 227:680-685 (1970)) as described above. Next to contactin, a 130 kD cell adhesion molecule of the immunoglobulin supergene family, T-cadherin is the major concanavalin A-binding glycoprotein of the complex (Ranscht et al., J. Cell Biol. 99:1803-18113 (1984)). The migration of T-cadherin on SDS-PAGE gels under reducing and non-reducing conditions is closely similar, suggesting that few or no intrachain disulfide bonds are present. Protein complexes containing T-cadherin, contactin, actin and approximately 15 other polypeptides were enriched by differential centrifugation and ion-exchange chromatography. The isolated protein complexes resist extraction with a variety of detergents in different salt conditions; thus, the individual components can only be dissociated from the complexes under denaturing conditions. T-cadherin can be purified by SDS preparative gel electrophoresis with a yield of approximately 50  $\mu\text{g}$  from 50 g starting material.

## EXAMPLE II

Protein Microsequencing

Proteins contained in brain polypeptide complex (BPC) were separated by preparative SDS-PAGE and electrophoretically transferred to a polyvinylidene difluoride membrane (Millipore, Burlington, MA) by methods well known to those skilled in the art. The 90 kD T-cadherin polypeptide was identified by staining the transferred proteins with Coomassie Brilliant Blue R250, excised and sequenced directly. Transfer conditions and processing were as described by Matsudaira, P., J. Biol. Chem. 262:10035-10038 (1987).

## EXAMPLE III

Generation and Affinity Purification of  
Anti-T-Cadherin Antiserum

The detergent-resistant polypeptide complex was separated into its individual components by preparative SDS-PAGE gel electrophoresis. The 90 kD T-cadherin fragment was excised from several Coomassie-blue stained gels, electroeluted and desalted on exocellulose GF5 (Pierce, Rockford, IL). A New Zealand white rabbit was immunized by intramuscular and subcutaneous injections of 100 µg 90 kD T-cadherin polypeptide in Freund's complete adjuvant (1:1). The rabbit was boosted three times in four week intervals with an identical amount of protein in Freund's incomplete adjuvant. Final boosts were intravenous with 50-100 µg protein in phosphate-buffered saline (PBS). Blood was collected 7-10 days after the injections. The antiserum was absorbed on bovine liver acetone powder.

For some experiments, affinity purified antiserum was used. Affinity purification was achieved with T-cadherin

immobilized by electrophoretic transfer onto polyvinylidene membranes (Millipore). The polypeptide complex was separated by SDS-PAGE and transferred to polyvinylidene membranes (Towbin et al., Proc. Natl. Acad. Sci. USA 76:356-375 (1979)). Proteins on the transfer were detected by staining with 1% amido black in methanol: acetic acid:water (20:10:70). The 90 kD T-cadherin peptide band was excised from the membrane and blocked for 30-60 minutes with 4% non-fat dry milk in TBST (10 mM Tris/HCl pH 8.0, 150 mM NaCl and 0.05% Tween 20). The T-cadherin strips were incubated with anti-T-cadherin antiserum (1:50 in TBST) for 2 hours at room temperature. Following washes in TBST, bound anti-T-cadherin antiserum was eluted from the strips with 600  $\mu$ l 0.1 M glycine, pH 2.5 for 5 minutes and neutralized immediately. The procedure was repeated five times to obtain sufficient quantities of purified antibody.

On immunoblots of nervous tissue homogenates, this antiserum recognized a major protein component of 90 kD. In addition, protein species of 110 and 120 kD were detected with the antiserum (Figure 4). The 110 kD polypeptide is likely to represent T-cadherin with the prepeptide, since both the 90 and the 110 kD species are obtained after transfection of COS-cells with T-cadherin cDNAs. The 120 kD protein is immunoprecipitated with the T-cadherin antiserum after  $^3$ H-ethanolamine labelling indicating that this protein is also GPI-linked to the membrane. Therefore, the 120 kD polypeptide is likely to be a nervous system specific form of T-cadherin. In contrast to neural tissue, the T-cadherin antiserum recognizes only the 90 and 110 kD protein species in non-neural tissue samples. Microsequencing of the 17 NH<sub>2</sub> terminal amino acids of the 90 kD protein and mapping of this sequence to the protein conceptually translated from the cDNA sequence indicates that the 90 kD protein is a fragment of T-cadherin that starts at amino acid residue



117 (Figures 2a and 2b) and excludes the signal and the prepeptide.

#### EXAMPLE IV

##### Immunoblotting Procedures

5 Various tissues including brain, retina, muscle, liver, heart and kidney were homogenized in buffer A (see EXAMPLE I) and separated by SDS-PAGE. Separated proteins were electrophoretically transferred to a polyvinylidene difluoride membrane. Marker lanes were stained separately  
10 with 0.1% amido black in methanol:acetic acid:H<sub>2</sub>O (20:10:70) and destained in the identical solution without the dye. For immunoblotting, non-specific binding sites were blocked as described above and the blots incubated for 60 minutes with anti-T-cadherin antiserum (1:150 for both the non-  
15 purified and the purified antiserum). Following washes in TBST, bound antibodies were detected with 1  $\mu$ Ci/ml <sup>125</sup>I goat anti-rabbit immunoglobulin (ICN Biochemicals Inc., Costa Mesa, CA) followed by autoradiography using Cronex Lightning Plus screens. In some experiments the blots were  
20 reacted using alkaline phosphatase conjugated goat anti-rabbit immunoglobulin and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) as enzyme substrates (Protoblot, Progema, Madison, WI) or the ECL Western Blotting detection system (Amersham Corporation,  
25 Arlington Heights, IL).

#### EXAMPLE V

##### Phospholipase Digestion of Cultured Sympathetic Neurons

Sympathetic ganglia were dissected from 10 day old chicken embryos in L15 medium. The ganglia were  
30 dissociated after a 30 minute digestion with 0.25% trypsin in PBS and plated in L15 culture medium onto culture dishes

coated with laminin (5  $\mu$ g/ml, Telios Pharmaceuticals, Inc., La Jolla, CA) at a density of  $1.4 - 1.8 \times 10^6$  cells/60 mm culture dish. The culture medium was supplemented with 10% dialyzed fetal calf serum, 0.5% methylcellulose, 2 mM glutamine, 0.6 g/l glucose, nerve growth factor and antibiotics. Extensive nerve fiber growth was observed after a 48-hour culture period.

For phospholipase digestion, 48 hour cultures were extensively washed with PBS. The cultures were incubated for 60 minutes at 37°C with 5U/ml phosphoinositol specific phospholipase C (PI-PLC, a gift from Dr. M. Low, Columbia University, New York) in PLC-buffer (PBS containing 1 mM phenylmethylsulfonyl fluoride, 50  $\mu$ M leupeptin, 5  $\mu$ M pepstatin, 4 ng/ml aprotinin and 5  $\mu$ g/ml  $\alpha_2$ -macroglobulin). The released material was collected, freed of cellular debris by centrifugation and concentrated 10 fold by ultrafiltration. The neuronal cells were peeled off the laminin substrate, washed with PLC-buffer and homogenized in 200  $\mu$ l H-buffer (10 mM Tris/HCl, pH 7.5, 2 mM  $\text{CaCl}_2$ , 2% Nonidet-P40, 0.25 mM dithiothreitol and protease inhibitors phenylmethylsulfonyl fluoride, leupeptin, pepstatin, aprotinin as above). Detergent-soluble and insoluble material was separated by centrifugation at 100,000 g for 45 minutes at 4°C. Control samples received PLC-buffer only; in two experiments 5 mM  $\text{ZnCl}_2$  was included during the digestion with the phosphoinositol specific phospholipase.

Released and cellular components of the PI-PLC treated cultures were separated by SDS-PAGE and analyzed on Western blots. In control samples (no additions), T-cadherin was found in the detergent soluble and insoluble fraction of the cells. T-cadherin was not detectable in the supernatant after the 60 minute incubation period. In contrast, when cells were treated with PI-PLC, essentially all of the T-cadherin was released into the supernatant

after 60 minutes. This release was blocked by  $\text{ZnCl}_2$  treatment of cells, an inhibitor of PI-PLC.

T-cadherin is secreted into the culture medium over longer culture periods ( $\geq 18$  hours). In the culture medium, T-cadherin appears in a highly soluble form as well as in association with an insoluble complex of extracellular matrix components that is pelleted by centrifugation of the culture supernatant at 100,000 g for 3 hours.

10

## EXAMPLE VI

Labeling with  $^3\text{H}$ -Ethanolamine and Fluorography

Cultures of sympathetic neurons were grown for 48 hours and then labeled for 18 hours with  $^3\text{H}$ -ethanolamine (100  $\mu\text{Ci/ml}$ ; specific activity 19-24 Ci/mmol (Amersham, Arlington Heights, IL) in supplemented L15 medium. Labeled cultures were either treated with phosphatidylinositol-specific phospholipase C as described below or processed immediately for analysis. The cells were lysed in H-buffer (10 mM Tris/HCl, pH 7.5, 2 mM  $\text{CaCl}_2$ , 2% Nonidet-P40, 0.25 mM dithiothreitol and protease inhibitors: 1 mM phenylmethylsulfonyl fluoride, 50 mM leupeptin, 5  $\mu\text{M}$  pepstatin, 4 ng/ml aprotinin) and the proteins separated by SDS-PAGE. Gels were stained with Coomassie Brilliant Blue R250, destained and equilibrated in water. For fluorography processing, the gels were equilibrated in dimethylsulfoxide (DMSO) for 30 minutes and then treated for 60 minutes with 20% 2,5-Diphenyloxazole (PPO) in DMSO. Gels were dried after extensive washing in water and exposed for 4-12 weeks with presensitized Kodak XAR-5 film.

## EXAMPLE VII

Immunoprecipitation

T-cadherin was immunoprecipitated from  $^3\text{H}$ -ethanolamine labeled sympathetic neuronal cultures. Following the labeling period, as in EXAMPLE IV, the cultures were thoroughly washed and lysed with 150 mM NaCl in 10 mM Tris/HCl, pH 7.0, 150 mM NaCl, 1% Deoxycholate, 1% Nonident-P40, 0.2% sodium dodecylsulfate, 1 mM phenylmethylsulfonyl fluoride, 50  $\mu\text{M}$  leupeptin, 5  $\mu\text{M}$  pepstatin, 4  $\mu\text{g/ml}$  aprotinin and 1 mM dithiothreitol. The lysate was cleared by centrifugation at 16,000 g for 30 minutes at 4°C. T-cadherin was complexed from the soluble protein pool with anti-T-cadherin antiserum (1:50) for 60 minutes at 4°C. The antigen/antibody complexes were precipitated with fixed staphylococcus aureus (Pansorbin, Calbiochem, La Jolla, CA). Precipitates were washed by centrifugation at 3000 g for 20 minutes through layers of 5%, 10% and 20% sucrose. The precipitates were resuspended in SDS-PAGE loading buffer (Maniatis et al., Supra) and analyzed by SDS-PAGE followed by fluorography as described above.

## EXAMPLE VIII

Immunocytochemistry

The localization of T-cadherin was examined using indirect immunofluorescence techniques. Chicken embryos between day 2 and 8 of embryonic development were staged using the criteria of Hamburger and Hamilton (J. Morph. 88:49-192 (1951)) (H & H). The animals were fixed by immersion into PLPA-fixative (100 mM Na-periodate, 75 mM lysine and 3% paraformaldehyde in PBS) or 4% paraformaldehyde alone for 1-3 hours depending on their size. The tissue was kryoprotected by successive immersion into 5% and 10% sucrose in PBS for 8-12 hours, embedded in

Tissue-Tek (Miles Laboratories Elkhart, IN) and frozen at -70°C. Serial sections of 15  $\mu$ m thickness were cut on a kryostat and collected on gelatine/chromalum (1% gelatine/0.4% chromalum) coated slides. Sections were  
5 stained for 3-4 hours at room temperature with rabbit anti-T-cadherin (1:100). Bound antibodies were detected with FITC or TRITC conjugated goat anti-rabbit IgG (1:150, Cappel Laboratories, Inc., Westchester, PA) Antibody dilutions were in GST-PBS (10% normal goat serum and 0.02%  
10 Triton-X100 in PBS), washes after each incubation step with PBS only. Stained sections were mounted with immunomount containing 2% 1,4-Diazabicyclo- (2.2.2)-octane (Aldrich, [Milwaukee, WI) to prevent rapid bleaching.

In the developing spinal cord at stage 20 (Figure 8b,  
15 panel 1) (H & H), motor neurons are in their early phase of differentiation and axon extension. Commissural axons that project from dorsolateral and dorsomedial sites to the floor plate region have commenced to extend processes towards the floor plate that serves as their intermediate  
20 target. At this stage of development, T-cadherin was found to be expressed on the cell bodies and nerve fibers of motor neurons and on ventral neuroepithelial cells including the floor plate. Other neurons or their precursors were not stained at this early stage.

25 At stage 24 (Figure 8b, panel 2), the majority of commissural axons have crossed the ventral midline of the spinal cord projecting through the ventral ridge of the floor plate. At this stage, the staining intensity of T-cadherin was strikingly increased in the floor plate  
30 region. Comparatively little staining was detected in other areas of the neural tube. The pattern of T-cadherin expression includes the floor plate epithelial cells as in previous stages and a segment of the commissural axons as they cross this area. This pattern suggests that  
35 commissural axons are stained by anti-T-cadherin only in

the segment in contact with the floor plate. The expression in the floor plate region was transient, since in older animals little staining or none can be detected in the floor plate area.

- 5        Motor neurons select as their intermediate targets the anterior region of the somitic sclerotome (Keynes and Stern, Nature 310:786-789 (1984)), thus establishing a segmental pattern of nerve projections. In coronal sections of stage 22-23 chicken embryos, T-cadherin was  
10    expressed in a striking segmental pattern on the surface of posterior somite cells (Figure 8a, panel 1). The spinal nerve fascicles crossing the anterior somite regions were identified in an adjacent section with anti-contactin antibodies (Figure 8a, panel 2). The segmental pattern of  
15    T-cadherin expression was observed as early as neural crest cells enter the somite regions.

#### EXAMPLE IX

##### Identification of cDNA Clones Encoding T-cadherin

- A cDNA library generated from embryonic day 13 chicken  
20    brain (Ranscht, J. Cell Biol. 107:1561-1573 (1988)) was screened for cDNA clones encoding T-cadherin. Nitrocellulose replica filters of a  $\lambda$ gt11 expression library from embryonal day 13 chick brain were screened with affinity purified anti-T-cadherin antiserum (1:40).  
25    Screening was essentially as described by Maniatis, incorporated herein by reference. Alkaline phosphatase conjugated goat anti-rabbit immunoglobulin and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro blue tetrazolium (NBT) substrates (Protoblot, Progema) were used  
30    as a detection system. In the initial screening one clone was isolated from  $7 \times 10^5$  amplified and  $8 \times 10^4$  unamplified recombinants. This clone represented a true T-cadherin transcript by two criteria:

1) The cDNA encoded a fusion protein that was recognized by anti-T-cadherin antiserum. Affinity purification of the antiserum on recombinant fusion protein selected antibodies specific for the 90 kd protein in brain homogenates on Western blots. Moreover, the affinity purified antiserum stained in indirect immunofluorescence on sections of stage 22-23 chick embryos posterior somite segments.

2) Conclusive evidence that the selected cDNA represented a T-cadherin transcript was obtained by comparison of the conceptually translated cDNA sequence with the amino acid sequence obtained by microsequencing of the NH<sub>2</sub>-terminus of the 90 kd protein. The 17 NH<sub>2</sub>-terminal amino acids of the 90 kd polypeptide mapped to amino acids 117 to 133 in the open reading frame of the protein conceptually translated from the cDNA sequence (See Figures 2a and 2b).

20

## EXAMPLE X

Isolation of Additional T-cadherin cDNA Clones

Sixteen additional cDNA clones for T-cadherin were isolated by screening both  $\lambda$ gt10 (amplified) and  $\lambda$ gt11 (unamplified) chick brain libraries with T-cad 2 restriction fragments that were labeled by nick translation (Maniatis et al., Supra; kit from Bethesda Research Laboratories Gaithersburg, MD). The restriction fragments constituted nucleotides 440-1559 of the initially isolated clone and included the coding sequences encoding the NH<sub>2</sub>-terminus of the 90 kD protein. Phage plaques were transferred in duplex to Hybond nylon membranes (Amersham, Arlington Heights, IL). The filters were processed successively through 1.5 M NaCl/0.5M NaOH for 2 minutes,

3 M Na-acetate, pH 5.2 for 5 minutes and 20 x SSPE (3 M NaCl, 0.2 M  $\text{NaH}_2\text{PO}_4$  x  $\text{H}_2\text{O}$ , 0.02 M  $\text{Na}_2$  EDTA, pH 7.4), dried and baked for 60 minutes in a vacuum oven. Prehybridization was at 42°C in 50% deionized formamide, 5x  
5 SSPE, 1x Denhardt's and 100 µg/ml salmon sperm DNA for 2-4 hours. Hybridization was overnight under identical conditions with the probe at  $2 \times 10^6$  cpm/filter. The filters were washed under high stringency conditions (0.2 x SSPE/0.2% SDS at 68°C) and exposed overnight to Kodak  
10 XAR-5 film.

All clones shared restriction sites within their internal nucleotide sequence, but varied in length from 1 to 3.8 kb. EcoRI restriction fragments of all clones were subcloned into the Bluescript KS+ vector (Stratagene, La  
15 Jolla, CA) and used for nucleotide sequence determination using a double stranded DNA as a template. Sequence over internal EcoRI sites was obtained from lambda cDNA templates. The nucleotide sequence of clone 266 (= T-cad 1), one of the longest cDNA clones (3.8 kb) and of cDNA  
20 1212 (= T-cad 2) are shown in Figures 2a and 2b.

Several cDNA clones were isolated from human  $\lambda$ gt11 embryonic brain library (Clontech). One clone contains the coding sequence of human T-cadherin starting at amino acid 23 (lacking extreme amino terminus) of Figure 2. Homology  
25 of chick T-cadherin to human T-cadherin is approximately 80%.

#### EXAMPLE XI

##### RNA Isolation

Total cellular RNA was isolated from hatched chicks by  
30 the guanidinium isothiocyanate method (Maniatis et al., Supra). Briefly, the tissues were homogenized on ice in 4 to 6 mls of 4 M guanidinium thiocyanate (GTC) buffer per



gram of tissue (94.4 g GTC, 1.67 ml 3 M sodium acetate, pH 6.0, 0.5% sarkosyl, 200  $\mu$ l antifoam A, 500  $\mu$ l 1 N NaOH, to 200 ml with DEPC treated dd H<sub>2</sub>O, 0.1 M final concentration of 2-mercaptoethanol should be added just prior to use).

- 5 The homogenate is layered onto 4 to 5 mls of 5.7 M CsCl solution in a SW 40 centrifuge tube (Beckman, Carlsbad, CA). The CsCl solution is prepared in the following manner: 95.97 g CsCl, 0.83 mls 3 M sodium acetate pH 6.0, to 100 mls with DEPC-dd H<sub>2</sub>O and filter sterilize. The tubes
- 10 are balanced with GTC buffer and the samples are centrifuged at 32,000 rpm for 18 hours using an ultracentrifuge (Sorvall, Newtown, CT). Following centrifugation, the GTC buffer and CsCl solution is aspirated off leaving about 1 ml of CsCl solution covering
- 15 the RNA pellet. The walls of the tube are rinsed with 1 to 2 mls of GTC buffer and the buffer, including CsCl layer, is carefully removed. The tubes are cut 1-2 cm from the bottom using a hot razor blade and the RNA pellets are rinsed with 400  $\mu$ l of 20°C ethanol, dried and resuspended
- 20 in Tris-EDTA (TE; 10 mM Tris-HCl, pH 7.6, 1 mM EDTA). The resuspended RNA is purified by extracting twice with an equal volume of phenol/chloroform followed by ethanol precipitation and washing as described above. RNA was quantitated by absorbance at 260 nm ( $OD_{260}$  of 1 = 50  $\mu$ g/ml).
- 25 Purity was checked by determining the absorbance ratio at 260 nm compared to the absorbance at 280 nm ( $OD_{260}/280 \geq 2.0$  for RNA). The RNA samples were stored as ethanol precipitates at -70°C until further use. From tissues of early developing chicken embryos, RNA was prepared by
- 30 lithium precipitation as described in Maniatis, Supra. When probed with T-cadherin cDNA, two transcripts of approximately 9.5 and 7.5 kb were detected.

## EXAMPLE XII

RNase Protection

RNA transcripts encoding the T-cadherin prepeptide and 3' untranslated regions were generated by in vitro transcription of T-cadherin cDNA. The template for the prepeptide probe (common to T-cad 1 and T-cad 2) was a 274 bp EcoRI restriction fragment (Figure 2b) from  $\lambda$ gt11 T-cad 2 cloned into Bluescript KS<sup>+</sup>. The fragment was linearized by digestion with HindIII in the polylinker region. A specific 3' end probe of T-cad 1 was generated by removing 1.5 kb untranslated sequence from the extreme 3' end of clone T-cad 1 by restriction digestion with StuI/SmaI and religation of the blunt ends. A 168 bp template was obtained by linearizing T-cad 1 DNA with SfaI. A specific 3' end template for T-cad 2 was generated by cloning its 2.1 kb EcoRI restriction fragment into Bluescript KS<sup>+</sup> and digestion of the cDNA fragment with HpaI. Chicken  $\beta$ -actin cDNA (kindly provided by Dr. D. Cleveland, Johns Hopkins University, Baltimore, MD) was used as a control. The  $\beta$ -actin cDNA was digested with KpnI and HindIII and cloned into the SP72 transcription vector (Melton et al., Nucleic Acids Res. 13:7035-7056 (1984)). The DNA was linearized by digestion with PvuII. The templates were transcribed in anti-sense orientation in the presence of T7 RNA polymerase and <sup>32</sup>P-rUTP under conditions described by Melton, Supra. Probes were purified on polyacrylamide gels. A 1% aliquot of the total probe was hybridized overnight in 80% formamide, 400 mM NaCl, 4 mM PIPES and 1 mM EDTA at 45°C to 2-10  $\mu$ g total RNA from various tissues. Non-hybridized RNA was digested with RNases A and T1 for 60 minutes at room temperature. RNA hybrids were separated on polyacrylamide gels and analyzed after exposure to Kodak XAR-5 film.

All tissues that show a protected fragment with the prepeptide probe, also showed a protected fragment with the

3' fragment, indicating that mRNA encoding the phosphoinositol linked form of T-cadherin exists in the tissues. Brain, heart, retina, cultured sympathetic neurons, stage 37 and 24 spinal cord (especially floor plate), and somites revealed protected fragments.

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

#### EXAMPLE XIII

##### Expression Vectors and Transfection of CHO-Cells

To generate full length T-cadherin plasmid DNA, T-cadherin cDNA-266 identified according to Example IX was released from  $\lambda$ gt11 by partial digestion with EcoRI (0.0625U/ $\mu$ g DNA for 30 minutes) and subcloned into Bluescript KS (Stratagene, La Jolla, CA) according to the manufacturer's instructions. For expression in eukaryotic cells, a plasmid, pcD-Tcad, containing the coding region of T-cadherin was generated. A T-cadherin DNA fragment was excised from Bluescript by digestion with NotI and StuI and ligated into the EagI/EcoRV polylinker sites of the eukaryotic expression vector pcDNA1 (Invitrogen, La Jolla, CA).

CHO-DG44 cells were transfected by calcium phosphate coprecipitation with pcD-Tcad and pSV2neo, a well-known plasmid carrying neomycin resistance (American Type Tissue Culture Collection). Cells were grown in alpha-formulated MEM (Gibco, Gaithersburg, MD or Sigma, St. Louis, MO) containing 10% fetal calf serum (FCS, Tissue Culture Biologicals, Tulare, CA) plus 1X HT supplement (Sigma), 2

mM L-glutamine, 1 mM sodium pyruvate, and nonessential amino acids (Gibco) and plated at a density of  $4.5 \times 10^5/6$  cm dish. After 16 hours in culture, 5  $\mu$ g calcium phosphate precipitated pcD-Tcad or pcDNA1 vector plus 1  $\mu$ g pSV2neo plasmid were added in fresh culture medium. After further 24 hours in culture, the cells were split 1:3 into 10 cm dishes and G418 (geneticin, Gibco) was added to a final concentration of 1 mg/ml. After 12-15 days G418-resistant colonies were isolated using cloning chambers and examined for cell surface expression of T-cadherin by indirect immunofluorescence with anti-T-cadherin antiserum. Several colonies were picked, and one was enriched by fluorescence activated cell sorting for the cells expressing the highest levels of T-cadherin. These cells were used for all aggregation experiments. For controls, CHO-cells were transfected with both the pcDNA1 and the pSV2neo vectors and cells from the G418 resistant colonies were examined by Southern blot analysis for the incorporation of pcDNA1 into genomic DNA. One pcDNA1 positive colony was chosen as control. Control CHO-cells do not express T-cadherin by indirect immunofluorescence and Western blot analysis.

#### EXAMPLE XIV

##### Aggregation Assays

For aggregation assays, the transfected CHO-DG44 cells were washed twice with 5 ml Hanks balanced salt solution (HBSS; Gibco) containing 1 mM  $\text{CaCl}_2$  and suspended by incubation at 37°C for 20 minutes in 25 mM HEPES buffered HBSS (HHBSS) containing 0.014% trypsin and 0.9 mM  $\text{CaCl}_2$ . The reaction was stopped by the addition of an equal volume of 0.02% soybean trypsin inhibitor in HHBSS and the cells were washed and resuspended at 4°C in HHBSS containing 1 mg/ml bovine serum albumin (BSA). Resuspended cells were incubated with 1 mM  $\text{MgCl}_2$  and 50  $\mu$ g/ml DNase I for 30 minutes at 37°C to remove any residual DNA that might

increase the background aggregation. Cells ( $1 \times 10^5$ ) in HHBSS plus BSA were incubated in a volume of 0.5 ml in Linbro uncoated 24 well dishes at 37°C and rotated at 90 rpms for 30 minutes. Aggregation was started by the addition of 1 mM  $\text{CaCl}_2$  and was stopped by the addition of 500  $\mu\text{l}$  of 5% glutaraldehyde in HHBSS (final concentration of 2.5%). The aggregates were mixed gently and the particle numbers were determined on a Coulter Model Z<sub>1</sub> with a 100  $\mu$  aperture. The percent aggregation was determined by the formula  $(N_0 - N_t)/N_0 \times 100\%$ , where  $N_t$  was the particle number at time  $t = 30$  minutes and  $N_0$  was the starting particle number. The cell viability was determined by trypan blue exclusion before the cells were aliquoted into the 24 well dishes.

For cells treated with phosphatidylinositol-specific phospholipase C (PI-PLC) before aggregation, 40  $\mu\text{l}$  of PI-PLC was added prior to the 30 minute incubation with DNase I. For those experiments in which cytoskeleton disrupting agents were used, either cytochalasin D (Calbiochem) or nocodazole (Calbiochem) or DMSO (Sigma) were added along with the DNase I and the cells were incubated at 37°C for 30 minutes. The aggregation assays were then performed as described.

For mixing experiments, the cells were labeled by incubation for 30 minutes at 37°C with 10 pM carboxyfluorescein diacetate succinimyl ester (CFSE; Molecular Probes, Inc., Junction City, OR). This labeling was either done as a monolayer of cells in regular media prior to trypsin treatment or subsequent to trypsin treatment. Cells were treated with trypsin as described above and incubated at  $1-2 \times 10^5$  cells per cell type in a total of 500  $\mu\text{l}$  of HHBSS, 1 mg/ml BSA, 1 mM  $\text{CaCl}_2$ . Photographs were taken of live cells using a heated (37°C) microscope stage on a Zeiss Axiovert 405M. The results are shown in Figures 9 and 10.

Figures 9a and 9b show that T-cadherin mediates homophilic cell adhesion. Figure 9a is a phase contrast photomicrograph showing several aggregates. Figure 9b is a fluorescence photomicrograph of labeled, non-transfected cells in the same field. A comparison of Figures 9a and 9b shows that the non-transfected cells remain as single cells and are non-adhesive, whereas cells transfected with the T-cadherin gene tend to aggregate.

Figure 10 shows the percent aggregation of T-cadherin transfected cells compared with various controls. The results indicate that aggregation is significantly higher for T-cadherin transfected cells compared to the control cells and the PI-PLC treated cells.

To determine the surface distribution of T-cadherin subsequent to cell aggregation, cells were processed and allowed to aggregate as described above. After 10 minutes, formaldehyde was added to 3% and the cells were rotated for 10 minutes. The cells were carefully washed with PBS and resuspended in PBS containing anti-T-cadherin antiserum (1:100) and incubated at room temperature with gentle rocking for 40 minutes. The cells were washed with PBS twice and incubated with FITC conjugated goat F(ab')<sub>2</sub> anti-rabbit IgG diluted 1:50 for 40 minutes. The cells were washed and resuspended in PBS for examination.

The results are shown in Figure 11. Figure 11a shows the phase contrast photomicrograph of the surface distribution of T-cadherin after aggregation. Figure 11b shows the fluorescence photomicrograph of the aggregate in the same field. T-cadherin appears to be concentrated in areas of cell-cell contact. These results indicate that T-cadherin induces cells to adhere to each other.

## I CLAIM:

1. A substantially purified polypeptide comprising T-cadherin.
2. The substantially purified polypeptide of claim 1, wherein the T-cadherin comprises T-cad 1 having a glycosyl phosphatidylinositol linkage in the cell membrane and no cytoplasmic domain.
3. The substantially purified polypeptide of claim 1, wherein the T-cadherin comprises T-cad 2.
4. An isolated nucleic acid sequence which encodes the polypeptide of claim 2 or 3.
5. Antibodies specifically reactive with T-cadherin, but not N-, E- or P-cadherin.
6. Antibodies of claim 5, wherein the antibodies are polyclonal.
7. Antibodies of claim 5, wherein the antibodies are monoclonal.
8. A method of detecting the presence of T-cadherin in a subject comprising contacting a sample from the subject with the antibody of claim 5 and detecting the binding of the reagent with T-cadherin, the presence of  
5 binding indicating the presence of T-cadherin.
9. A nucleic acid probe comprising nucleic acid sequences sufficiently complementary to portions of the nucleic acid of claim 4 to allow hybridization.

10. A method of detecting the presence of T-cadherin in a subject, comprising contacting the probe of claim 9 with a sample from the subject containing nucleic acids and determining binding of the probe to the nucleic acid, the presence of hybridization indicating the presence of T-cadherin.

11. An expression vector comprising the nucleic acid of claim 4, wherein the vector is capable of expressing T-cadherin in a transformed host cell.

12. A transformed host cell comprising the vector of claim 11 in a suitable host cell.

13. Polypeptides produced by the transformed host cells of claim 11.

14. A method of inhibiting tumor cell migration comprising increasing tumor cell adhesion with an effective amount of T-cadherin.

15. The method of claim 14, wherein T-cadherin is inhibited in a tumor with a therapeutically effective dose of ligand or reagent which binds with T-cadherin.

16. The method of claim 15, wherein the ligand or reagent is an antibody which reacts with T-cadherin but not N-, E- or P-cadherin.

17. The method of claim 15, wherein the reagent is an oligonucleotide or cDNA which encodes T-cadherin, but not N-, E- or P-cadherin.

18. A method of repairing traumatized neurons of a subject comprising treating traumatized neurons with a therapeutically effective dose of T-cadherin.



1/20




FIG.1

## FIG.2A-1

1 GAATTCGAATGAAAAAGCCTCTGGTACGTTCTAGTCTGGCAAAATGCAGCACAAAACTCAACTTACTCTGTCTCTTCTGTCTGTCCCG  
 -22 M Q H K T Q L T L S F L L S Q  
 90 GTTCTGTTGCTTGGCTGTCAGAGATTAGAAATGCACCCCTGGATTCCAGCAAAAGGTTTTTATATATGAACAGCCATTGAAATTCACA  
 -7 V L L L A C A E D L E C T P G F Q Q K V F Y I E Q P F E F T  
 180 GAGGACCGCAATTCTGAACCTGGTGTGATGACTGCAAGGGGAATAACAATTGAACCTCGAAGTTTCTAACCCAGACTTTAAAGGTG  
 24 E D Q P I L N L V F D D C K G N N K L N F E V S N P D F K V  
 270 GAACACGATGATCTTTAGTTGCACTGAAGAATGTATCAGAAGCTGGCAGAGCTTTGTTGTCCATGCACGGTCTGAGCATGCTGAGGAT  
 54 E H D G S L V A L K N V S E A G R A L F V H A R S E H A E D  
 360 ATGGCAGAAATTTGATTGTTGGAGCTGATGAGAAGCAGATGCATTAAGGAAATCTTTAAGATAGAGGCAACCTTGGAATTCCAAGA  
 84 M A E I L I V G A D E K H D A L K E I F K I E G N L G I P R  
 450 CAAAAAGGGCTATTCTGGCGACTCCAATATTAATCCAGAAAAATCAAGAGACCACCATTTCCCAGATCAGTTGGCAAGGTCATCAGGAGT  
 114 Q K R A I L A T P I L I P E N Q R P P F P R S V G K V I R S  
 540 GAAGGACAGAGGGAGCAAAAGTTCCGACTCTCTGGTAAGGGAGTAGATCAAGACCCGAAAGGAATTTTAGAATCAATGAGATCAGTGGG  
 144 E G T E G A K F R L S G K G V D Q D P K G I F R I N E I S G  
 630 GATGCTCTGTGACCCGACCCCTGGATAGAGAGCAATAGCCAATATGAGCTGGAGTTGAAGTAACGGATTAAAGTGGGAAAATCAT  
 174 D V S V T R P L D R E A I A N Y E L E V E V T D L S G K I I  
 720 GATGCCCCAGTCCGCTTAGATATTTCTGTTATTGATCAAAATGATAACAGGCCGATGTTCAAAGAAGGACCCCTATGTTGGTCACGTCATG  
 204 D G P V R L D I S V I D Q N D N R P M F K E G P Y V G H V M  
 810 GAAGGATCCCTACAGGAACAACCTGTGATGCGGATGACAGCATTTGATGCTGATGATCCTAGCACAGACAACGCTCTTCTGCGGTATAAC  
 234 E G S P T G T T V M R M T A F D A D D P S T D N A L L R Y N  
 900 ATCTCAAGCAGACACCTACCAAAACCTTCCCCAAATATGTTCTACATTGACCCAGAAAAGGGAGATATTGTACAGTGGTGTACCTGTGTA  
 264 I L K Q T P T K P S P N M F Y I D P E K G D I V T V V S P V

## FIG.2A-2

990 CTGCTGGATCGTGAGACAATGGAACGCCGAAGTACGAGCTGGTTATTGAAGCCAAGGATATGGCGGCCATGATGTGGACTTACTGGA  
 294 L L D R E T M E T P K Y E L V I E A K D M G G H D V G L T G  
 1080 ACTGCAACTGCCACTATTCTTATTGATGACAAAACGACACCCAGCAATTTACCAAGAAGGAGTTTCAGGCCACAGTAAAGGAAGGA  
 324 T A T A T I L I D D K N D H P P E F T K K E F Q A T V K E G  
 1170 GTCACAGGAGTAATAGTAACTTAACCTGTTGGTGACCGGAGATGACCCAGCAACTGGAGCATGGAGAGCTGTCTACACTATTATTAAACGGA  
 354 V T G V I V N L T V G D R D D P A T G A W R A V Y T I I N G  
 1260 AATCCAGGGCAGAGTTTGAATCCATACCAATCCCCAGACTAATGAGGGAATGCTCTCTGTGTCAAACCTTTAGACTATGAGATTCA  
 384 N P G Q S F E I H T N P Q T N E G M L S V V K P L D Y E I S  
 1350 GCATTTCACACATTGCTGATATAAAGTAGAAAATGAAGACCCGTTGATTCCAGACATAGCCTACGGTCCAGTTCACAGCAACAGTTCAG  
 414 A F H T L L I K V E N E D P L I P D I A Y G P S S T A T V Q  
 1440 ATCACCGTTGAGGATGTGAATGAAGGCCCTGTTTCCACCCAAACCCAAATGACAGTGACAAAACAGAGAACATCCCTATTGGCAGCATT  
 444 I T V E D V N E G P V F H P N P M T V T K Q E N I P I G S I  
 1530 GTGTTAACAGTAATGCCACTGATCCAGATACTTTGCAACATCAGACTATCAGGTATTTCAGTTTACAAGGATCCAGCAAGCTGGCTAGAG  
 474 V L T V N A T D P D T L Q H Q T I R Y S V Y K D P A S W L E  
 1620 ATTAATCCCACCAATGGTACCGTTGCCACCCACTGCTGTCTGGATCGGGAATCTCCTCATGTTTCAGGATAACAATAACACTGCTCTCTTC  
 504 I N P T N G T V A T T A V L D R E S P H V Q D N K Y T A L F  
 1710 CTGGCAATAGACAGTGGTAACCCCTCCTGCTACAGGTACAGGAACCTTACACATCACCTTGGAGGACGTCAATGACAATGTCCCCCTCCCTT  
 534 L A I D S G N P P A T G T G T L H I T L E D V N D N V P S L  
 1800 TACCCAAACACTGGCAAAAGTCTGTGATGATGCTAAAGATCTCAGAGTAGTGGTACTAGGAGCATCAGACAAAGACCTCCATCCCAACACA  
 564 Y P T L A K V C D D A K D L R V V L G A S D K D L H P N T  
 1890 GATCCATTAAATTTGAACCTGAGTAAGCAATCTGGTCCAGAAAAGTTATGGAGAATCAACAAGCTTAACAATACTCATGCCCCAGGTTGTC  
 594 D P F K F E L S K Q S G P E K L W R I N K L N N T H A Q V V

FIG.2A-3

1980 CTGCTTCAAACCTGAAAAAGGCCAATTACAACATCCCAATCTCAGTGACAGATTCTGGAAAAACCACTCTGACTAACACACAGAACTG  
 624 L L Q N L K K A N Y N I P I S V T D S G K P L T N N T E L  
 2070 AAATTACAAGTGTGTTCTCTGCAAGAAATCCAGAAATGGACTGCAGTGCAGTGATGCCCTTCATATCAGCATGACTCTTATCCTTCTTTCA  
 654 K L Q V C S C K K S R M D C S A S D A L H I S M T L I L L S  
 2160 CTCTTCAGTTTATTTGTCTGTAGGAACCTCCTGACATTTGAAGCTGTCTACCGAGTTGCCATGGCAACGAGAAAAAGAAACGTCAGA  
 684 L F S L F C L \*  
 2250 TCTGAAGACTGCAGTTTACAGTTACTGTTCTTCACTACTAGGCCTCAGTTGCTCCAGATTTCAGTTTAAATTTGCAACCTCACTTAATCTGT  
 2340 CCGACTATACATTTGTTGACAGCCTCTGCCCTAACTTCCATTTATTAATGATTCTCTTGCAGATGCAAGTTTATGCGAATTTT  
 2430 CACTGAATGTTAAAGACCATGACATCTAACTTGACCTTTGGGAGCAGAAAAACAGATTGACTCCATTTTCTTAACCTGTGACTTGT  
 2520 TGCTATTCAACTGTTTCAGAAAAATATTTGCTGTGGTTAGTATTTGATATGATGATGATGATATATATATATATATATATATATGAG  
 2610 AGAAGAGTTATAGGACTGGTTTAGCTTTTATAAAATATTCATCTGGAATGTGCAATGACAAAGCAGAGTAATACAGCCACAGATGAATC  
 2700 ATAACTATTCAACATGGCTAAACCTACTGTACTTGTGTTTATAGTGTGGCCAGAGGAGCCTATTGCAGTCATACCACTGAAAAAAG  
 2790 CCACCTTTGTTGACACCAATAAGGCAGGCCGCTCTGCAGCATCACTTCTTGTACCTCAGGTTTCAGCAACAGGAAATGCAAGTCCC  
 2880 CCGGCTTGCTTCTGATCCGACTTCTCACCTTATGCCCCAAACTGACTTTAAGACTCAGCGGGAGCACATCTCTTCACTCAGTGCCGG  
 2970 GAGGTAACGCAAGCTCTCACCTGTAAAGGCAAGGGAAGCACTCAGCACAGCCACCATATGTTGCTGGGCGAGTTTACAAAATTTAAGTCCCTT  
 3060 TGGGCTGATTTTAAAGGGCTAAACTCAGCTTCCCTATGCTCTTSCAGATAATTTTGTGGGCGAGTTTACAAAATTTAAGTCCCTT  
 3150 GTCAGTTCTGCAGACGAAGTAGTAATGCTGCTTATGAGAAGCTGATTAGAACAGCAAAATCAAGGTGTTTCCAGAACACTGGCCTC  
 3240 TCTCTCAGCCTCTGTGCAGCTGTCTATACATGTATCAGTGCAGGAGGAAACAGATGCCCTATTATCTAAGTGTATTCACACATATCTA  
 3330 TAGTTTGAATATATATACATACATACACGTGTACACAGTTTCCAGTTAAGAGTAACAGAGCATTTCTTTGTGTGTGTAAACTTA  
 3420 CCACACTTGTGTGCAGACATGGGGAAGGTTGTTTACATATGACTATGAATCCTTTTATCTGTGAGCATGTAAAGTTTAA  
 3510 AAAAGAAAAAATTAAGTATCAAGATGATCATCTTGTGTTAATAATTTGTAATGATCCATCAAGCTCACACCAATTTTATATAAAT  
 3600 AACACAGAAAAAGTATACAGTGCAGACTGTGGCTTTTATAGAGCTTGGCAGTAACCTAGGTAAGGTAGTGTCTTAGAATATTTAAT  
 3690 AATCTTGCTTATTTAAAGTTTAAACAAGAAAGCTTCTTATGCAATAGTACTTTGACGTGCAATCTTTAGTTAGCATTTTACAGTACC  
 3780 TATGAGTCATACGTATGTTGCTTTTACTACAGTGAGATTATGAGCATATCTTCCACACCATATATGTTTCAATAGTAAAGTTTGTG  
 3870 GAAGCATTAAGAGTCCCAACATACACTGAGTTTTCATACAGCTACACTAGATATTTAAATGTGTGTGTGTTTAAAGAAAAA

FIG.2B-1

1 GAATTCCAAAAGCCTCTGGTACGTTCTAGTCTGGCAAAATGCAGCACAAAACCTCACTTACTCTGTCTTTCTGTCTCCAGGTTCTG  
 -22 M Q H K T Q L T L S F L L S Q V L  
 91 TTGCTTGCCTGCAGAGATTTAGAATGCACCCCTGGATTCCAGCAAAAGGTTTTTATATTGAACAGCCATTGGAATTCACAGAGGAC  
 -5 L L A C A E D L E C T P G F Q Q K V F Y I E Q P F E F T E D  
 181 CAGCCAAATCTGAACCTGGTGTGATGACTGCAAGGGGAATAACAAATTGAACCTTCGAAGTTTCTAACCAGACTTTAAGGTGGAACAC  
 26 Q P I L N L V F D D C K G N N K L N F E V S N P D F K V E H  
 271 GATGGATCTTTAGTTGCACCTGAAGAATGTATCAGAAGCTGGCAGAGCTTTGTTGTCCATGCACGGTCTGAGCATGCTGAGGATATGGCA  
 56 D G S L V A L K N V S E A G R A L F V H A R S E H A E D M A  
 361 GAAATTTTGATTGTTGGAGCTGATGAGAAGCACGATGCATTAAAGGAAATCTTTAAGATAGAAGCAACCTTGGAATTTCCAAGACAAAAA  
 86 E I L I V G A D E K H D A L K E I F K I E G N L G I P R Q K  
 451 AGGGCTATTCTGGCGACTCCCAATATTATTCAGAAATCAAGACCCAGCCACTTTCCAGATCAGTTGGCAAGGTCAATCAGGAGTGAAGGG  
 116 R A I L A T P I L I P E N Q R P P F P R S V G K V I R S E G  
 541 ACAGAGGGAGCAAAAGTTCCGACTCTCTGTAAGGGAGTAGATCAAGACCCGAAAGGAATTTTGAATCAATGAGATCAGTGGGATGTC  
 146 T E G A K F R L S G K G V D Q D P K G I F R I N E I S G D V  
 631 TCTGTGACCCGACCCCTGGATAGAGAAGCAATAGCCCAATTATGAGCTGGAAGTTGAAGTAACGGATTAAAGTGGGAAAATCATTGATGGC  
 176 S V T R P L D R E A I A N Y E L E V T D L S G K I I D G  
 721 CCAGTCGCGCTAGATATTCTGTTATTGATCAAAATGATAACAGGCCGATGTTCAAGAAGGACCCCTATGTTGGTCACGTCATGGAAGGA  
 206 P V R L D I S V I D Q N D N R P M F K E G P Y V G H V M E G  
 811 TCCCCTACAGGAACAACCTGTGATGCGGATGACAGCATTTGATGCTGATGATCCTAGCACAGACAACGCTCTTCTCGGGTATAACATCCTC  
 236 S P T G T T V M R M T A F D A D D P S T D N A L L R Y N I L

## FIG.2B-2

901 AAGCAGACACCTACCAAACCTTCCCAATAATGTTCTACATTGACCCAGAAAAGGAGATATTGTCACAGTGGTGTGCGCTGTACTGCTG  
266 K Q T P T K P S P N M F Y I D P E K G D I V T V V S P V L L  
991 GATCGTGAGACAAATGGAACCGCGAAGTACGAGCTGGTTATTGAAGCCAAGGATATGGGCGGCCCATGATGTGGGACTTACTGGAACCTGCA  
296 D R E T M E T P K Y E L V I E A K D M G G H D V G L T G T A  
1081 ACTGCCACTATTCTTATTGATGACAAAAACGACCCACCAGAAATTTACCAAGAAGGAGTTTCAGGCCACAGTAAAGGAGGAGTCACA  
326 T A T I L I D D K N D H P P E F T K K E F Q A T V K E G V T  
1171 GGAGTAATAGTAAACTTAACCTGTTGTGACCGAGATGACCCAGCAACTGGAGCATGGAGAGCTGTCTACACTATTATTAAACGGAATCCA  
356 G V I V N L T V G D R D D P A T G A W R A V Y T I I N G N P  
1261 GGCAGAGTTTGAATCCATACCAATCCCAGACTAATGAGGGAATGCTCTCTGTTGTCAAACCTTTAGACTATGAGATTTCAGCATTT  
386 G Q S F E I H T N P Q T N E G M L S V V K P L D Y E I S A F  
1351 CACACATTGCTGATAAAAGTAGAAAATGAAGACCCCGTTGATTCCAGACATAGCCTACGGTCCCAGTTCACAGCAACAGTTTCAGATCACC  
416 H T L L I K V E N E D P L I P D I A Y G P S S T A T V Q I T  
1441 GTTGAGGATGTGAATGAAGGCCCTGTTTTCCACCCCAACCCCAATGACAGTGACAAAACAAGAGAACAATCCCTATTGGCAGCATTTGTGTTA  
446 V E D V N E G P V F H P N P M T V T K Q E N I P I G S I V L  
1531 ACAGTAAATGCCACTGATCCAGATACTTTGCAACATCAGACTATCAGGTATTACAGGTTCAGCAAGCTGGCTAGAGATTAAT  
476 T V N A T D P D T L Q H Q T I R Y S V Y K D P A S W L E I N  
1621 CCCACCAATGGTACCGTTGCCACCACCTGCTGCTGGATCGGGAATCTCCGCATGTTTCAGGATAACAATACTGCTCTCTTCCTGGCA  
506 P T N G T V A T T A V L D R E S P H V Q D N K Y T A L F L A  
1711 ATAGACAGTGGTAACCTCCTGCTACAGGTACAGGAACCTTTACACATCACCTTGGAGGACGTCAATGACAATGTCCCTCCCTTTACCCA  
536 I D S G N P P A T G T G T L H I T L E D V N D N V P S L Y P

## FIG.2B-3

1801 ACAC TGGCAAAAGTCTGTGATGATGCTAAAGATCTCAGAGTAGTGGTTCTAGGAGCATCAGACAAAGACCTCCATCCCAACACAGATCCA  
566 T L A K V C D D A K D L R V V L G A S D K D L H P N T D P

1891 TTTAAATTGAACTGAGTAAGCAATCTGGTCCAGAAAAGTTATGGAGAATCAACAAGCTTAACAATACTCATGCCCCAGGTGTCTCTGCTT  
596 F K F E L S K Q S G P E K L W R I N K L N N T H A Q V V L L

1981 CAAAACCTGAAAAGGCCAATTACAACATCCCAATCTCAGTGACAGATTCTGGAAAACCCACTCTGACTAACAAACACAGAACTGAAATTA  
626 Q N L K K A N Y N I P I S V T D S G K P L T N N T E L K L

2071 CAAAGTGTTCCTGCAAGAAATCCAGAAATGGACTGCAGTGCAGTGATGCCCTTCATATCAGCATGACTCTTATCCTTCTTTCACTCTTC  
656 Q V C S C K K S R M D C S A S D A L H I S M T L I L S L F

2161 AGTTTATTTGTAAAGTCTTTTCCTTATGTGTAAAGCATTGAACGTTATTTATCTCTGCTTGCTTTTGCACTATAAGAAACCTTACCAAGAGAG  
686 S L F C K S F P Y V \*

2251 AAGTTAACTTTTATTTTCCCTGCGGTAGATGCTATACAGAAGTAGGAGGGAGGGATTTTTCACAGTCAAAAAATAGCAACAAATGCCG  
2341 GGTGTCAAAATTAGAAATAGAAAGCAATAATTCTAGGAAGAATCAAGAGAAATTAAGCTAGCATATGATAACTAAGAGTACCAGCTG  
2431 TAGTAACAGATTCTGAGATGCTTTCTTTCATCTCTCCCTTGAATTCATCAAAAGCAGAACTGAAGATTAAAAAGGTGTCTTGT  
2521 AACAAATAACTGTTCTGGGTCACCATGAAAATGAGTACTGTCTGCTTCAATCTATTTGTCCGTAAGTGCCGAGCAATTGGACATAAGG  
2611 AACTTACTGAAGATTCTGGGTTTAGAGACACTCAAACTGATAACCAAGATAGCAGGTCTGTGTTGAGGGAGAGAGAACTGATGCATAAG  
2701 GAAGCTTCTGCTCTTAGAGAAAAGCTTTCTAAAAGTCTTATGAATTCCTAATCTGAATTAGGAGTTTAAAGGAATTC

FIG.3A

```

SIG T M Q H K T Q L T L S F L I S Q V L . I I A C A . . . . .
N M C R I A G T P P R I I P P L A L M I I A A L Q Q A P I
L M G A R C R S F S A L I I I L Q V S S W L C Q E L E P :
P M E L L S G P H A F L I I I L L Q V C M I R S V V S E P :

PRE T . . . . . E D L E Q I P G F Q Q K V . F Y I E Q P F E F T E . D Q P I L N L V F D D C K G N K L N F E V S N P . D F K V E H D G S L V
N K A T C E D M L C K M G E P E D M . H S A V V S R S V H G . G Q P L L N V R E Q S C D E N R K I T Y E G S S E P E D F R V G E D G V V Y
L . . . . . D S V A A . G R E L G R V S F A A C S . G R P W A V V P I D T R I F K V N G D G V V S
E . . . . . E S C S P G F S S E M . Y T F P V P E R H L E R G H V L G R V R E E G C T . G R P R T A F F S E D S R E K V A T D G T I T
P . . . . . Y R A G E I G E A G V T L E V E G T D L E P S Q V L G K V A L A G Q G . . . . .

EC1 T A I L A T P I L I P E N Q R . P P F P R S V G K V I R S E G T E G A . . . . . K F R L S . . . . . G K G V D Q D P K G T F R I N E T S
N D W V I P P I N L P E N S R . G P E P Q E L V R . I R S K R D K S L . . . . . S L R Y S V T G P G A D Q P P T I G I F I I N P I L S . . . . .
L D W V I P P I S C L E N H R . G E P T M R L V Q . I K S N K D K E S . . . . . K V Y S I T G Q G A D S P P V G I H I I E R E T . . . . .
E D W V I P P I S C P E N E K . G E P K N L V Q . I K S N R D K E T . . . . . K V F Y S I T G Q G A D K P P V G V F I I E R E T . . . . .
P E W V M P P I F V P E N G K . G P E P Q R L N Q . L K S N K D R G T . . . . . K I F Y S I T G P G A D S P P E G V E T I E K E S . . . . .

EC2 T K E G P V G C H M E G S P T G T I I V M . . . . . R M T A F E D A D D . P S I D N A L R Y N I L K Q I P T K P S P N M R V I D P E K . . . . .
N L H Q V M N G T M P E G S K P G T I V M . . . . . T V T A I D A D D . P N A Q N G M L R Y R I L S Q A P S S P S P N M F I I N N E I . . . . .
L I K E V F V G Y I E E N A K P G T S V M . . . . . T V N A I D A D D A V N T D N G I V S Y S I V S Q Q P P R P H Q M F I I D P A K . . . . .
E T Q E V F E G S V A E G A V P G T S V M . . . . . K V S A I D A D D A V N T I N A A I A M T I V S Q D P E L P H K N M F I V N R D T . . . . .
P T Q D T F R G S M I E G V M P G T S V M . . . . . Q V I A T D E D D A V N D Y N G V V A L S I H S Q E E K E P H D I M E T I H K S T . . . . .

EC3 T I I K K E F Q A I M K E G . V I G V I V . N I . I T V G . . . . . D R D D . P A I T G A W R A V Y T I I N G N . . . . . P . G Q S E E T H I N P Q I N
N I A M T I Y G E M P E N . R V D V I V A N L . I T V I . . . . . D K Q Q . P H I P A M A R V Q M T G G D . . . . . P I T G Q . F I T I I I D P N S N
L N P T M Y E G V M E E N . K P G T E V A R L . I V T . . . . . D Q D A . P G S P A M Q A V Y H I I K S G N . . . . . L D G A . F S I I I D P S I N
E N P S T Y G G Q M P E N . E V N A R I A T L . K V I . . . . . D D D A . P N I P A M K A V Y I V . N D . . . . . P D Q Q . F V V V I D P I I L N
P E P Q K Y E A M P E N . E V G H E M Q R L . I V T . . . . . D L D V . P N W P A W R A T Y H I V G E D . . . . . D G D H . E T I T H P E I N

```



FIG.3B

```

A. LKNVSEAGRALF. MHAR. SEHAE. DMAEIDT. VGADEKHDAKKEIFKTEGNLGIP. ....RQKR
AERSFQLSAEPTERFVWSARDKETQEWQVKLT. PEPAFTGASEKQDKKIEDIIFPWQQYKDSSSHLPKQKR
TKRPLTLYGRKISFTLYAQDAMGKR. HSARVTV. GRHRHRRHHHNNHLLQDTPAVLTFPKHDPGFLRRQKR
VKRHLKLHKLETSELVARDSSHPH. LSTKVTV. KSMGCHHHHRRHHRDPASESNPELLMFPSSVYPG. LRRQKR
.....MHADNGQIIMLTRGTVQGGKDHMSPPTRILRRKR
.....

GDVSVTRP. LDRE. ....ATANYEEVEVTDLSGKIIDG. ....PVRLDTSVIDQNDNRPMF
GQLSVTKP. LDRE. ....QIASFHLRAHADVAVNGQVEN. ....PLDIVINVIDVNDNRPEF
GWLKVTEQ. LDRE. ....KIIDRMITLLSHAVSASGPVED. ....PMEIITITVMDQNDNKPVF
GWLKVTOP. LDRE. ....ATAKMJLYSHAVSSNGEAVED. ....PMEIVITITVMDQNDNRPEF
GWLLLHME. LDRE. ....KIJVKYELIGHAVSENCAVEE. ....PMNISIMITDQNDNKPKF
.....

GDIMTWSPVLLDRE. ....TMEITPKVELVIEAKDMGGHDV. ....GLTG. ....TATATITLIDDKNDHPPEF
GDIIITMAAG. LDRE. ....KVGGMITLITUGATDMEGNPTY. ....GLSN. ....TATAMITVTDVNDNRPEF
GHIISVLGTG. LDRE. ....ITIPNMITLIVGATDCEGK. ....GLSN. ....TATATIEVTDANDNTPTDF
GVIISVLTSG. LDRE. ....SYPTMITLVGADLQGE. ....GLST. ....TAKAMITVKDIINDNAPMF
GHSVVISGG. LDRE. ....KVEPMRLTVGATDMGCE. ....GSTIT. ....TAEAVQMLDANDNAPPEF
.....

E. G. MLSVVKP. LDYE. ....ISAFHTDLI. KVE. NEDPILIPDITAYGSS. ....TATVQITVEDVNE. GPVF
D. G. LVTWVKP. LDYE. ....TNRMFVLTV. AAE. NQVPLAKGTHPEQS. ....TATVSLTVIDVNE. SPVF
N. G. ILKTA. KG. LDYE. ....TKSRVDLVV. TVE. NKVPIS. VPITLS. ....TASMLVTVLDVNE. PPVF
D. G. ILKTA. KG. LDYE. ....AKQYJLHV. RVE. NEEPFE. GSLVPS. ....TATVTVMDVNE. APVF
Q. G. VLTTK. KG. LDYE. ....AQDCHTLVV. EM. NEAPFA. VKLPTA. ....TATVWVHMKDVNE. APVF
.....

```

FIG.3C

EC4 T HPNPMITKQENIPIGSIML...TAVATDPDTLQHQT...IRYSVYKD...PASHLET...NPTN.  
N VNPKLMRQEEGLAGSMI...ITFAROPDRYMQQT...SIRYSKLS...PANWLEI...DPVN.  
L VPPIKRMGVPEDLVGGQMT...SYTAEDPDRDMRQ...KITTYRMGSD...PAGWLYJ...HPEN.  
E MPAERRMEVPEDEFGVQET...SYTAREPDIFMDQ...KITTYRIWRD...JANWLEI...NPET.  
P VPBSKVTEAQEGUSIGELMC...IYTAQDPDKE.DQ...KITSUTISRQ...PANWLAIV...DEDS.

EC5 T SLYPTLAKVQDDAKDLRVM...VLGASDKDHPNTIDPKFELSCKSGPE...KL.M...RINKLN..N  
N QVNPKEATTCETLQPNAIN...LTAVDPDIDPNAGPFAEELPD.SPESI...KRNW...TIVRIS..G  
L TPEPRSFELCSR.QPEKQI...LSIVOKDIPPHIYPEKAALEH.GSS...NNM...TVEIRG..Q  
E IPEPRNMQFCQR.NPQPHI...LTIILDPDIPNTISPPITAE.LTH.GAS...VNM...TMEYNDAAG  
P IPEPRQIICNQ.SVPVQM...DNITDKQLSPNSSPEQAQLTH.DS.DI...YM...MAEVSE.KG

TM T .....ALHISMILILLSLFSDFCQ\*  
N ..IVGAGLGTGAIILALICIIILILMLMFVWVM  
L :IVG.GLGVPAIILGGLGILALILILLLLLLFA  
E AGIVAAGLQVPAIILGGLGILALILILLLLLLFL  
P .....G.GFILP.ILGAV...LAULTILALLLLLV

CP T KRRDKERQAKQLLIDPEDDVRDNIKYDEEGGGEEDQDYDLSQLQ.QPDTVEPDAIKPVGIRRLDER  
N RRRKVEKEP..LLP.PEDDMRDNVYNYDEEGGGEEDQDYDLSQLHRGLDAR.PEVI.....RNDVA  
L RRRTVVKEP..LLP.PDDTTRDNVYNYDEEGGGEEDQDYDLSQLHRGLDAR.PEVT.....RNDVA  
P RKKRKVKEP..LLL.PEDDTRDNVYNYDEEGGGEEDQDYDITQLHRGLDAR.PEVL.....RNDVV

T HPGDIGDFINEGLKAANDPTAPPYDSLLVFDYEGSGTAGSLSSLNSSSSSGGEQDYDYLNDWGNRF  
N NPDEIGNFIDENLKAADTPTAPPYDSLLVFDYEGGGSEATSLSSLNSSASDQDQDYDYLNEWGNRF  
L NPDEIGNFIDENLKAADSDPTAPPYDSLLVFDYEGSGSEAAASLSSLNSSSEDQDQDYDYLNEWGNRF  
E NPDEIGNFIENLKAANTDPTAPPYDSLMVFDYEGSGSDAAASLSSLTTSASDQDQDYNYLNEWGSRF  
P NPDEIGNFIENLKAANTDPTAPPYDSLMVFDYEGSGSDAAASLSSLTTSASDQDQDYNYLNEWGSRF

..GIVATTAV..LDRESP..HVQDNKNTALFLAID..SGNPPATG.....TGTLLHITLEDVNDNVP  
..GQITITAV..LDRESI..YVQNMNNATELASD..NGIPPTSG.....TGTLLQIYLLDINDNAP  
..GIMVITQP..LDRESV..HALNSTYKALILAND..NGIPDITG.....TGTLLLLILDVNDNGP  
..GAIIFIRAE..MDREDAEHVKNSTYVALIJAID..DGSPIATG.....TGTLLLVLLDVNDNAP  
..GQI..JAAGI..LDREDEGFVKNNVMEVMVLAID..SGNPPITG.....TGTLLLLITDINDHGP  
..  
THAQVVL...LQNLKKN...YNIPIISVID..SGKPIPLTNNTETKLQVCSCK..KSRMDCSASD  
DHAGLSL...RIRFLEAGI...YDVPJIVITD..SGNPHASSTSLKVKVCCQCD..ING.DCTDVR  
DELAMGL...KKELLEPGE...YNIIFVKLID..SQGK.AQVTQVTKAGVCECEGTAKN..CERRSY  
ESLILQP...RKDLLEIGE...YKIHKLKAD..NQNKD.QVT..ILDVHVCDCEGTVNN..CMK  
DTVALSD...KKFLKQDT...YDLHLSLSD..HGNRE.QLT.MIRATVDDCHGQVFNDCIPRPWK  
..

FIG.3D

P.IHAEPQYPVRSAAP  
PPLMAAPQYRPRPA..  
PTLMSVPQYRPRPA..  
PTFIPTPMYRPRPA..  
  
KKLADMYGGG.DD\*  
KKLAELYGGGEDDE\*  
KKLADMYGGGEDD\*  
KKLADMYGGGEDD\*

12/20




FIG.4




FIG.5A




FIG.5B




FIG.6




FIG.7





FIG.8A-1

SUBSTITUTE SHEET





**FIG.8A-2**

**FIG.8A-3**



**FIG.8B-1**



**FIG.8B-2**



**FIG.8B-3**




FIG. 8C





FIG. 8D

SUBSTITUTE SHEET



**FIG.9A**

**FIG.9B**




FIG.10

SUBSTITUTE SHEET

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**